CPhG alleviates oxaliplatin-induced peripheral neuropathy by dual mechanisms: reducing neuroinflammation via IL-6 suppression and promoting neuronal survival and regeneration through AKT activation and m6A-dependent epitranscriptomic regulation. Compared with duloxetine, CPhG demonstrated superior neuroprotective and anti-inflammatory effects, supporting its potential as a novel therapeutic agent for OIPN.

HQGZWWT significantly ameliorated CINP by increasing sciatic nerve conduction velocity, reducing oxidative stress and inflammatory responses, and inhibiting ferroptosis. Both HQGZWWT and its active monomeric component paeoniflorin protect neurons by suppressing ferroptosis, thereby exerting preventive and therapeutic effects against CINP. These findings provide new insights into the clinical treatment of CINP with HQGZWWT. Inhibiting ferroptosis by regulating the p38/c-FOS/NF-κB pathway through HQGZWWT and its primary monomeric component paeoniflorin represents a promising therapeutic strategy for preventing and treating oxaliplatin-induced CINP.

P=N/A, N=30, Not yet recruiting, Tongde Hospital of Zhejiang Province; Tongde Hospital of Zhejiang Province

P=N/A, N=150, Recruiting, Linyi Tumor Hospital; Linyi Tumor Hospital

P2, N=106, Recruiting, Jiangsu Hengrui Medicine Co., Ltd.; The First Affiliated Hospital of Nanchang University

P2, N=30, Recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital

P2, N=236, Recruiting, The Sixth Affiliated Hospital of Sun Yat-sen University; The Sixth Affiliated Hospital of Sun Yat-sen University | Not yet recruiting --> Recruiting

Variants in FGFR signaling pathway-related factors were significantly associated with capecitabine-induced HFS.

Furthermore, the sustained-release gel facilitated a more precise and efficient anti-tumor strategy by promoting apoptosis, inducing immunogenic cell death (ICD), and orchestrating profound changes in key intra-tumoral pathways and networks, such as Stat1-Src and the complement system. Collectively, this study provides a strong theoretical rationale and technical foundation for the application of thermosensitive hydrogel-mediated local chemotherapy-immunotherapy in postoperative colorectal cancer treatment.

Postoperatively, the patient received 4 cycles of XELOX chemotherapy plus nivolumab, followed by consolidative radiotherapy synchronized with capecitabine and nivolumab, and subsequent maintenance therapy with capecitabine and nivolumab until sustained no evidence of disease (NED) was confirmed in January 2023. This exceptional and sustained response may be attributed to the synergistic effect of TMB-H and POLD1 mutation, which enhance neoantigen generation and sensitize tumors to immunotherapy. This case highlights the potential of biomarker-driven chemo-immunotherapy combined with MDT-guided multimodal treatment (surgery + adjuvant therapy + consolidative radiotherapy) to achieve curative intent in patients with metastatic GMC, providing valuable insights for personalized treatment strategies in this poor-prognosis population.

In CRC, CAF-derived exosomes (CAF-Exo) drive epithelial-mesenchymal transition, sustain stemness, stimulate angiogenesis, suppress antitumor immunity, and promote resistance to fluoropyrimidines and oxaliplatin...Therapeutic opportunities include blockade of exosome biogenesis or uptake, pharmacologic reprogramming of CAFs, and engineering vesicles to deliver targeted inhibitors or RNA-based therapeutics. This review synthesizes current mechanistic insights, evaluates biomarker potential, and outlines clinical priorities for targeting CAF-exosomal pathways in CRC.

IP PTX promotes the recruitment and activation of eosinophils with potent antitumor activity in the peritoneal cavity. Early post-treatment abdominal eosinophilia is a robust prognostic biomarker and may represent a promising therapeutic target to enhance the efficacy of IP chemotherapy in patients with PM from GC.